Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

Prophylactic tocilizumab has the potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies, explained Robert Rifkin, MD, FACP, a medical oncologist and ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

Celltrion announced on Friday that its biosimilar Avtozma, a version of the autoimmune disease treatment Actemra (active ingredient tocilizumab), has received product approval from the US Food and ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Table 3. Incidence of Grade ≥3 TEAEs Occurring in ≥10% of Patients Across Cohorts, Regardless of Attribution One patient with grade 3 CRS received tocilizumab in cohort 1 and three patients with grade ...

This is even without mandating preventative treatment like tocilizumab, and that paints as good a picture as we can see about the safety for now. Risk — CAR T-cell therapy is an aggressive ...